Can mepolizumab (Nucala) be used to treat eosinophilic granulomatosis with polyangiitis (EGPA) and what is the recommended dosing and monitoring strategy?

Mepolizumab for EGPA: Indications, Dosing, and Monitoring

Mepolizumab (Nucala) is FDA-approved and conditionally recommended for active, non-severe EGPA in combination with glucocorticoids, but should NOT be used for severe, organ-threatening or life-threatening EGPA where cyclophosphamide or rituximab are preferred. 1, 2

Disease Severity Classification Determines Treatment Choice

The critical first step is determining disease severity, as this dictates whether mepolizumab is appropriate:

Severe EGPA (life- or organ-threatening manifestations):

• Alveolar hemorrhage
• Glomerulonephritis
• Cardiac involvement
• Central nervous system vasculitis
• Mononeuritis multiplex
• Mesenteric ischemia
• Limb/digit ischemia

Non-severe EGPA:

• Predominantly asthma
• Sinus disease
• Non-severe vasculitis
• Mild systemic symptoms
• Uncomplicated cutaneous disease
• Mild inflammatory arthritis

2

When to Use Mepolizumab

Primary indication: Active, non-severe EGPA with relapsing or refractory disease, particularly when asthma and eosinophilic features predominate 2, 3, 4

Mepolizumab is the FIRST-LINE choice for non-severe EGPA over methotrexate, azathioprine, or mycophenolate mofetil, based on the MIRRA randomized controlled trial demonstrating efficacy in this population 2, 5

Do NOT use mepolizumab for:

• Active severe EGPA with organ-threatening manifestations (use cyclophosphamide or rituximab instead) 2, 3
• Initial remission induction in severe disease (patients with severe disease were excluded from the pivotal trial) 2, 6

FDA-Approved Dosing

Standard dose: 300 mg subcutaneously every 4 weeks 1

• Administered as three separate 100-mg injections
• Inject into upper arm, thigh, or abdomen
• Space individual injections at least 5 cm (approximately 2 inches) apart
• Always combine with glucocorticoids

Lower Dose Consideration

Real-world evidence suggests 100 mg every 4 weeks may be effective for some patients, particularly those with predominantly respiratory manifestations 7, 8, 9. A large European multicenter study of 203 patients found comparable complete response rates between 100 mg and 300 mg doses (35.7% at 24 months for both) 7. However, the FDA-approved dose remains 300 mg, and the lower dose should be considered off-label.

Practical approach: Start with FDA-approved 300 mg dose, but consider 100 mg in patients with:

• Limited respiratory manifestations
• Cost concerns
• Good initial response allowing potential de-escalation

Expected Clinical Outcomes

Based on the MIRRA trial 5:

• 28% of patients achieved ≥24 weeks of accrued remission (vs. 3% placebo)
• 32% achieved remission at both weeks 36 and 48 (vs. 3% placebo)
• 44% reduced glucocorticoid dose to ≤4 mg/day by weeks 48-52 (vs. 7% placebo)
• 50% reduction in annualized relapse rate (1.14 vs. 2.27)

Critical caveat: Only approximately half of patients treated with mepolizumab achieved protocol-defined remission 5. This is not a universally effective therapy.

Monitoring Strategy

Baseline assessment:

• Birmingham Vasculitis Activity Score (BVAS)
• Blood eosinophil count
• Pulmonary function tests
• Echocardiogram (conditionally recommended at diagnosis) 2
• Document glucocorticoid dose
• Assess asthma control and ENT symptoms

During treatment (every 4 weeks at injection visits):

• BVAS score
• Blood eosinophil counts (expect significant reduction) 7, 9
• Asthma exacerbations
• ENT exacerbations
• Glucocorticoid dose (aim for gradual taper)

Response timeline:

• Initial response assessment: 3 months
• Complete response rates increase progressively: 12.3% at 3 months → 30.4% at 12 months → 35.7% at 24 months 7

Treatment failure indicators:

• Persistent BVAS >0 despite 6+ months of therapy
• Inability to taper glucocorticoids below 7.5 mg/day
• Recurrent severe exacerbations
• Development of organ-threatening manifestations

Relapse Management

For non-severe relapse on methotrexate/azathioprine/mycophenolate:

• Add mepolizumab rather than switching agents 2

For non-severe relapse on low-dose glucocorticoids alone:

• Add mepolizumab over adding conventional immunosuppressants 2

For severe relapse:

• Switch to rituximab (preferred over cyclophosphamide re-induction) 3, 2

Safety Monitoring

Real-world studies show no new safety signals beyond those in clinical trials 10. The safety profile is favorable compared to conventional immunosuppressants 6.

Monitor for:

• Hypersensitivity reactions (rare)
• Infections (standard biologic precautions)
• Herpes zoster reactivation

Pneumocystis jirovecii prophylaxis: Not routinely required for mepolizumab alone, but conditionally recommended if patient is also receiving cyclophosphamide or rituximab 2

Adjunctive Respiratory Management

Optimize inhaled therapy concurrently:

• High-dose inhaled glucocorticoids + long-acting β2-agonists for asthma
• Nasal rinses and topical therapies for ENT involvement
• Involve pulmonology and otolaryngology specialists 4, 1

This multidisciplinary approach is essential because respiratory manifestations often have a course independent of systemic vasculitis 4.

Duration of Therapy

The optimal duration is not well-established. Real-world evidence suggests:

• Mean follow-up in studies: 16.3 months 10
• Some patients maintain remission after discontinuation 11
• One case report suggests extending dosing interval to 8 weeks may be feasible for stable patients in remission 12

Practical approach: Continue mepolizumab as long as clinical benefit persists and glucocorticoid-sparing effect is maintained, with periodic reassessment for potential de-escalation in stable patients.